

Accelr8 Announces First European Presentation of Rapid Diagnostic Results for New Drug Resistance Test

DENVER, Colo., February 22, 2011 – Accelr8 Technology Corporation (NYSE Alternext US: AXK) announced that clinical research collaborators at the Denver Health Medical Center received notification of acceptance for presentation of interim research results at the annual meeting of the American Thoracic Society (www.ats.org). The meeting will be held in May. The presentation will describe "early look" results from a clinical pilot study that uses Accelr8's BACcel™ rapid diagnostic system. The research uses specimens from ICU patients under an Institutional Review Board approved protocol with informed patient consent. Specific aims include comparison of diagnostic speed and accuracy against results from standard laboratory culturing. The BACcel™ system analyzes live microbial cells extracted directly from a patient specimen and eliminates the need for days of laboratory cultures. In previous research, the system demonstrated the ability to report quantitative identification within two hours after obtaining a specimen, and major drug resistance expression types within a total of six hours. Standard culturing methods require 2-3 days, which is too late to improve outcomes for critically ill patients who acquire drug-resistant infections with endemic hospital pathogens. The company also disclosed that it has begun to integrate its automated microscopy and fluidic robotics into a single instrument. The company established technical milestones in the second calendar quarter for specialty suppliers to demonstrate subsystems and integration feasibility. Based on supplier input, management believes that "alpha" systems will become available to international key opinion leaders in about one year. According to David Howson, Accelr8's president, "these two events reflect the substantial progress we've made in field studies and in making the transition to a fully automated hospital product. The May presentation offers the first exposure to the Pulmonary Medicine community for the BACcel™ system. The study itself is designed to answer important questions that researchers have not previously been able to address because there has been no method to quickly analyze emergent infections. Our system is now closing that critical gap," Howson concluded. In other news, the January issue of the Bowser Report featured Accelr8 as the Stock of the Month. Copies of the report are available at www.thebowserreport.com. About Accelr8 Accelr8 Technology Corporation (www.accelr8.com) is a developer of innovative materials and instrumentation for advanced applications in medical instrumentation, basic research, drug discovery, and bio-detection. Accelr8 is developing a rapid analytical platform for infectious pathogens, the BACcel™ system, based on its innovative surface coatings, assay processing, and detection technologies. In addition, Accelr8 licenses certain of its proprietary technology for use in applications outside of Accelr8's own products. Certain statements in this news release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements regarding future prospects and developments are based upon current expectations and involve certain risks and uncertainties that could cause actual results and developments to differ materially from the forward-looking statement, including those detailed in the company's filings with the Securities and Exchange Commission. Accelr8 does not undertake an obligation to publicly update or revise any forward-looking statements, whether as a result of new information or future events. Contact OR John Metzger, of Metzger Associates Tom Geimer, of Accelr8 Technology

<https://ir.axdx.com/accelr8-announces-first-european-presentation-of-rapid-diagnostic-results-for-new-drug-resistance-test-22-02-11>